Samplimy wins Money Talks Pitch Competition: aiming to transform the future of sampling

With a technology that enables painless and more accessible sampling, Samplimy took home first prize in the Money Talks Pitch Competition at the second Life Science Fair Flemingsberg of the year.

The medtech company develops solutions for microsampling, where biomarkers* are collected through painless methods directly from the skin. The technology is based on more than five years of research at KTH Royal Institute of Technology, and makes it possible for patients to collect samples of both blood and interstitial fluid (ISF)* themselves – without the use of traditional needles or the need to visit a clinic.

Samplimy is about unlocking access to biodata at frequency and scale by providing patient-centric sampling of blood and interstitial fluid. Today, clinical trials are expensive due to complex logistics and patients struggling with painful blood collection and repeated clinic visits. Our technology enables self-sampling that you barely notice, allowing for more time points and richer real-world data needed for the revolution we see in omics and AI models to deliver entirely new insights. In addition, microsampling can open the door to diagnostics for large parts of the global population currently lacking basic access, with the goal of facilitating healthcare’s shift toward more preventive and predictive care, says CEO Patrik Nilsson.

Their first product, which focuses on ISF and is aimed at researchers and life science companies within dermatology and skincare, is already being used in research studies and pilot projects. The latter for example together with Procter & Gamble in the US. At the same time, the company is also developing a blood-based product, with the aim of enabling more patient-friendly and decentralized clinical studies and screening programs.

Looking ahead, Samplimy’s focus is on scaling up the organization and product development, expanding ongoing collaborations and pilot studies, and initiating new studies. The win in the Money Talks Pitch Competition they view as a positive step in going forward.

The win means a lot, both as a stamp of quality and as confirmation that colleagues, investors, and the market see the same needs that we do – and that the hard work we put in is truly relevant”, says Patrik.

 

Interstitial fluid is the fluid found between cells in the body’s tissues and serves as a local source of information about what is happening in the body, where it happens.

Biomarkers are measurable indicators in the body that can provide information about health or disease.

Mando Group

“We conducted our research and development in collaboration with KI and Karolinska University Hospital here in Flemingsberg – work that paved the way for our insights into what causes obesity and ultimately its treatment. The positive environment at Campus Flemingsberg encourages original thinking and collaboration and has created a stimulating environment that has been decisive for us,” says Cecilia Bergh.

NextCell Pharma

“Flemingsberg is exactly the right place for us thanks to its proximity to collaboration partners and the clinical research conducted at Karolinska University Hospital. Furthermore, it’s the right place for us to grow given how Flemingsberg as a whole is flourishing and developing,” says Mathias Svahn.

Sprint Bioscience

In Flemingsberg, there is an opportunity for us to grow and offer a good working environment for our employees. Here are the benefits of proximity to research at Karolinska Institutet and clinical research at Karolinska University Hospital. We are also attracted by the fact that the area represents innovation and looks forward with excitement to the upcoming development and that we, together with the other Life Science companies in the area, will be an important part of the new Flemingsberg.

Go to Top